Information Provided By:
Fly News Breaks for February 14, 2020
Feb 14, 2020 | 09:38 EDT
Piper Sandler analyst Tyler Van Buren said he has been tracking the early launch experience with AbbVie (ABBV) and Allergan's (AGN) Ubrelvy ahead of approval for Biohaven Pharmaceutical's (BHVN) rimegepant, which is "expected any day now." The initial Ubrelvy prescription trajectory indicates a strong demand for oral CGRPs to treat acute migraine, said Van Buren, who said Ubrelvy's trajectory bodes well for Biohaven's rimegepant, which he views as a superior product. The analyst has an Overweight rating and $100 price target on Biohaven shares.